Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BY 4.0Digestive and Liver Disease

Anal neoplasm: Streamline follow-up of low-grade dysplasia

  • Aurore Carlo
  • Laurent Siproudhis
  • Amandine Landemaine
  • C Gouriou
  • Claire Grolhier
  • Astrid Lièvre
  • Sébastien Henno
  • Charlène Brochard
Open at sourcePDFDOICite

Abstract

Background: Screening strategies for anal cancer are based on repeated assessments in targeted populations. Low-grade lesions are frequently diagnosed, but the progression to invasive cancer is not the rule. The aim of the present study was to identify risk levels in these patients to refine screening strategies.Methods: The data of consecutive patients referred for screening of anal intraepithelial lesions were collected prospectively. Patients with low-grade intraepithelial lesions (LSILs) at referral and at least two clinical evaluations, including cytology and virology, were included. HPV DNA screening, high-grade lesion (HSIL) and invasive cancer incidence data were extracted.Results: From April 2010 to December 2020, 194 patients with LSILs were included, with a median follow-up of 48 months. The cumulative probabilities of HSILs were 13.7% [9.5-19.4] at 1 year and 44.4% [35.9-53.3] at 5 years. Past history of HIV, HPV lesions, HPV subtypes (except HPV16), tobacco consumption and body mass index were not significantly related to HSILs. HPV16 status and age older than 44 years at baseline were associated with a greater risk of HSIL.Conclusions: Patients with LSIL have a low risk of HSILs, except those with HPV16 subtype at baseline. After a first-year a reasonable recommendation may be a 4-year interval between two screening visits.

Related

  1. Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report
    Jiankai Long, Jingnan Xue, Nanzi Xie +2
    Frontiers in medicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  2. Human papillomavirus oncogene mRNA testing for anal dysplasia and anal cancer screening in men living with HIV
    Steffi Silling, Alexander Kreuter, Anja Potthoff +3
    International Journal of Medical MicrobiologyPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  3. Distinct Anaerobic Microbial Signature Differentiates Anal Squamous Cell Carcinoma From High-Grade Squamous Intraepithelial Lesions: A Prospective Metagenomic Study
    B. Nolasco, T. Lambert, K. Luo +8
    medRxivPreprintAll rights reservedFull textOncologymedRxiv
  4. Peripancreatic High-Grade Neuroendocrine Neoplasm Mimicking a Pancreatic Mass in Esophageal Small Cell Carcinoma
    Jyoti Yadav, Yame Shayah, Teodar Aleksa Lazic +2
    ACG case reports journalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Pancreatic solid papillary neoplasm with high-grade malignant transformation and multiple hepatic metastases in an elderly male: a case report
    Kuang-Ting Liu, Yueh-Ching Chang, Yu-Chieh Lin +1
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{carlo2026anal,
  title = {{Anal neoplasm: Streamline follow-up of low-grade dysplasia}},
  author = {Aurore Carlo and Laurent Siproudhis and Amandine Landemaine and C Gouriou and Claire Grolhier and Astrid Lièvre and Sébastien Henno and Charlène Brochard},
  journal = {Digestive and Liver Disease},
  year = {2026},
  month = oct,
  doi = {10.1016/j.dld.2025.09.013},
  url = {https://hal.science/hal-05341043v1},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Anal neoplasm: Streamline follow-up of low-grade dysplasia
AU  - Aurore Carlo
AU  - Laurent Siproudhis
AU  - Amandine Landemaine
AU  - C Gouriou
AU  - Claire Grolhier
AU  - Astrid Lièvre
AU  - Sébastien Henno
AU  - Charlène Brochard
PY  - 2026
DA  - 2026/10/30
JO  - Digestive and Liver Disease
DO  - 10.1016/j.dld.2025.09.013
UR  - https://hal.science/hal-05341043v1
AB  - Background: Screening strategies for anal cancer are based on repeated assessments in targeted populations. Low-grade lesions are frequently diagnosed, but the progression to invasive cancer is not the rule. The aim of the present study was to identify risk levels in these patients to refine screening strategies.Methods: The data of consecutive patients referred for screening of anal intraepithelial lesions were collected prospectively. Patients with low-grade intraepithelial lesions (LSILs) at referral and at least two clinical evaluations, including cytology and virology, were included. HPV DNA screening, high-grade lesion (HSIL) and invasive cancer incidence data were extracted.Results: From April 2010 to December 2020, 194 patients with LSILs were included, with a median follow-up of 48 months. The cumulative probabilities of HSILs were 13.7% [9.5-19.4] at 1 year and 44.4% [35.9-53.3] at 5 years. Past history of HIV, HPV lesions, HPV subtypes (except HPV16), tobacco consumption and body mass index were not significantly related to HSILs. HPV16 status and age older than 44 years at baseline were associated with a greater risk of HSIL.Conclusions: Patients with LSIL have a low risk of HSILs, except those with HPV16 subtype at baseline. After a first-year a reasonable recommendation may be a 4-year interval between two screening visits.
SN  - 1590-8658
ER  -